These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30889383)

  • 1. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
    Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
    Gravells P; Grant E; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    Coulson-Gilmer C; Morgan RD; Nelson L; Barnes BM; Tighe A; Wardenaar R; Spierings DCJ; Schlecht H; Burghel GJ; Foijer F; Desai S; McGrail JC; Taylor SS
    J Exp Clin Cancer Res; 2021 Oct; 40(1):323. PubMed ID: 34656146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
    Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death.
    Houl JH; Ye Z; Brosey CA; Balapiti-Modarage LPF; Namjoshi S; Bacolla A; Laverty D; Walker BL; Pourfarjam Y; Warden LS; Babu Chinnam N; Moiani D; Stegeman RA; Chen MK; Hung MC; Nagel ZD; Ellenberger T; Kim IK; Jones DE; Ahmed Z; Tainer JA
    Nat Commun; 2019 Dec; 10(1):5654. PubMed ID: 31827085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
    Pillay N; Brady RM; Dey M; Morgan RD; Taylor SS
    Prog Biophys Mol Biol; 2021 Aug; 163():160-170. PubMed ID: 33524442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
    Feng X; Koh DW
    Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
    Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK
    J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARG Inhibitors and Functional PARG Inhibition Models.
    Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
    Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
    Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase.
    Stowell AI; James DI; Waddell ID; Bennett N; Truman C; Hardern IM; Ogilvie DJ
    Anal Biochem; 2016 Jun; 503():58-64. PubMed ID: 27036617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
    Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
    Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADP-ribose).
    Okita N; Ashizawa D; Ohta R; Abe H; Tanuma S
    Biochem Biophys Res Commun; 2010 Feb; 392(4):485-9. PubMed ID: 20079708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
    Harrision D; Gravells P; Thompson R; Bryant HE
    Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
    Fathers C; Drayton RM; Solovieva S; Bryant HE
    Cell Cycle; 2012 Mar; 11(5):990-7. PubMed ID: 22333589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.